TetraLogic Pharmaceuticals Acquires Shape Pharmaceuticals for $13,000,000

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1c573583-fdb6-4d43-9150-0b5b3cb09916
Date
4/8/2014
Company Name
Shape Pharmaceuticals
Mailing Address
55 Cambridge Pkwy. Cambridge, MA 02142 USA
Company Description
Shape Pharmaceuticals, Inc. is developing a novel, topical HDAC inhibitor, SHP-141, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL).
Website
http://www.shapepharma.com
Transaction Type
M&A
Transaction Amount
$13,000,000
Transaction Round
Proceeds Purposes
M&A Terms
TetraLogic will make a $13 million up-front cash payment for Shape, followed by undisclosed potential development and commercialization milestones, as well as tiered royalties on product sales.